Churbz: "Please stop referring to my patience." I
Post# of 30028
Posted On: 02/19/2015 12:43:59 PM
Churbz: "Please stop referring to my patience." I think I've spoken to you about "patience" once.
I think my former stock is relevant to AMBS because after languishing for what seemed an eternity, it wasn't a partnership that got it moving, it was simply revenue.
I think things will start converging for AMBS in the next few months culminating in an IPO up list in May or June, in my opinion. I think we can get to .20 cents by then without a partner...just more Lympro contracts and Lympro CLIA launch and announcement of MS launch. I think if Gerald set a date for the IPO and up list and all our revenue generators converged by June, we'd take off.
I can still see us reach .50 cents to $1.00 by year end (Pre-RS) and without a partnership. (That's a 6 to 12 bagger this year. We'll get more for a partnership or Diagnostic Division sale in 2016.
Just my honest opinions. They could be wrong, of course. But that's par for the course in a stock like this. Yes, Gerald has made some mistakes, but he's also assembled an incredible pipeline ready to explode! I've already vented my criticisms of him and have moved on to what lies before us in the immediate future. That very believable potential is making me positive rather than negative.
I think my former stock is relevant to AMBS because after languishing for what seemed an eternity, it wasn't a partnership that got it moving, it was simply revenue.
I think things will start converging for AMBS in the next few months culminating in an IPO up list in May or June, in my opinion. I think we can get to .20 cents by then without a partner...just more Lympro contracts and Lympro CLIA launch and announcement of MS launch. I think if Gerald set a date for the IPO and up list and all our revenue generators converged by June, we'd take off.
I can still see us reach .50 cents to $1.00 by year end (Pre-RS) and without a partnership. (That's a 6 to 12 bagger this year. We'll get more for a partnership or Diagnostic Division sale in 2016.
Just my honest opinions. They could be wrong, of course. But that's par for the course in a stock like this. Yes, Gerald has made some mistakes, but he's also assembled an incredible pipeline ready to explode! I've already vented my criticisms of him and have moved on to what lies before us in the immediate future. That very believable potential is making me positive rather than negative.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼